Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COV2
- Development stage
- Phase 1
- Lead developer
- Rokote Laboratories
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intranasal
01
Overview
COV2 is an investigational nasal vaccine developed by Rokote Laboratories Finland Oy, designed to protect against COVID-19. It is based on a serotype 5 adenoviral vector that delivers the genetic information for the SARS-CoV-2 spike protein. The vaccine aims to induce an immune response by presenting the spike protein to the immune system, thereby conferring protection against the virus. It is being evaluated for safety and immunogenicity at different dose levels and administration methods (nasal drops and nasal spray) in both booster and vaccine-naive subjects.
- Other names
- FINVAC COVID-19Rokote Laboratories COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on COV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COV2.